Compras federais de antineoplásicos no Brasil: análise do mesilato de imatinibe, trastuzumabe e L-asparaginase, 2004-2013

Abstract

Observou-se redução nos PMP do imatinibe, mesmo antes da centralização da compra pelo MS. O PMP do transtuzumabe foi reduzido em 57% após a incorporação pela CONITEC e a centralização de compras. As quantidades e preços da L-asparaginase variaram entre os órgãos. Diferentemente dos outros medicamentos, verificou-se significativa elevação de 117% no PMP da L-asparaginase, refletindo o desabastecimento no mercado mundial. Conclusões: A inclusão em Parcerias de Desenvolvimento Produtivo e a centralização das compras pelo MS parecem justificar as reduções de preço do imatinibe e trastuzumabe, reforçando a tese do uso do poder de compra do Estado. Estas reduções podem contribuir na ampliação de seu acesso no SUS. Palavras-chave: assistência farmacêutica; preço de medicamento; antineoplásicos; compras públicas; parcerias público-privadas.

Demandas judiciais por medicamentos antineoplásicos: a ponta de um iceberg?

“…This reality, as well as the availability of multiple therapeutic choices for a specific cancer case, makes it difficult to define oncological protocols 28 . Under this perspective, the great majority of procedures follow the DDT rather than the PCDT.…”

Public procurement of medicines: scoping review of the scientific literature in South America

“…These purchases were justified by judicial demand in 82% of the cases. The judicial claim as reasoning for the purchase of medicines by government agencies is a topic discussed in four studies [13, 19–21]. These studies addressed the economic impact, the potential effects on the incorporation of new technologies [22, 23], and responsibilities of the federative entities in medicines acquisition and distribution.…”

“…The characterization of purchases involved data collection on medicine type, dose, volume of the purchase, unit price, date, reasoning of the purchase, and type of acquisition process including a diverse range of medicines [14, 17–19, 32–34] or a therapeutic class [20, 21, 35–37], with cost per capita estimation and, in some cases, comparison with international prices or prices of specific partnerships [35].…”

“…Although considered by two studies [12, 21], the issue of costs involved in purchase processes is barely discussed despite its great importance for the comparison of government programs. These costs include the payment of professionals and logistics for acquisition among other elements.…”

Organização e práticas da assistência farmacêutica em oncologia no âmbito do Sistema Único de Saúde

“…The interviewees highlighted problems of shortages of medicines provided by the Ministry of Health, considered essential for the treatment of cancer and / or that have a high cost 26 . Irregularities in the supply of medicines have been causes for effective enforcement of lawsuits 31 .…”